Roche Holding AG (RO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roche Holding AG (RO) has a cash flow conversion efficiency ratio of 0.296x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF11.23 Billion ≈ $14.20 Billion USD) by net assets (CHF37.88 Billion ≈ $47.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Roche Holding AG net asset quality index to measure how much of total assets are equity-financed.
Roche Holding AG - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Roche Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Roche Holding AG to evaluate the quality of earnings relative to operating cash generation.
Roche Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roche Holding AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MERCEDES-BENZ GRP ADR/1/4
F:DAII
|
0.029x |
|
GALDERMA GROUP AG
NYSE:GALDY
|
N/A |
|
Nasdaq Inc
NASDAQ:NDAQ
|
0.051x |
|
Autodesk Inc
NASDAQ:ADSK
|
0.152x |
|
Xcel Energy Inc
NASDAQ:XEL
|
0.071x |
|
Sandvik AB
ST:SAND
|
0.046x |
|
Ambev S.A.
SA:ABEV3
|
0.035x |
|
Delta Air Lines Inc
NYSE:DAL
|
0.119x |
Annual Cash Flow Conversion Efficiency for Roche Holding AG (1998–2025)
The table below shows the annual cash flow conversion efficiency of Roche Holding AG from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Roche Holding AG (RO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF37.88 Billion ≈ $47.89 Billion |
CHF17.83 Billion ≈ $22.54 Billion |
0.471x | -15.29% |
| 2024-12-31 | CHF36.16 Billion ≈ $45.72 Billion |
CHF20.09 Billion ≈ $25.40 Billion |
0.556x | +14.84% |
| 2023-12-31 | CHF33.26 Billion ≈ $42.05 Billion |
CHF16.09 Billion ≈ $20.35 Billion |
0.484x | -15.88% |
| 2022-12-31 | CHF32.02 Billion ≈ $40.48 Billion |
CHF18.41 Billion ≈ $23.28 Billion |
0.575x | -22.27% |
| 2021-12-31 | CHF28.34 Billion ≈ $35.84 Billion |
CHF20.98 Billion ≈ $26.52 Billion |
0.740x | +58.53% |
| 2020-12-31 | CHF39.77 Billion ≈ $50.28 Billion |
CHF18.57 Billion ≈ $23.47 Billion |
0.467x | -25.21% |
| 2019-12-31 | CHF35.87 Billion ≈ $45.35 Billion |
CHF22.39 Billion ≈ $28.30 Billion |
0.624x | -5.14% |
| 2018-12-31 | CHF30.37 Billion ≈ $38.39 Billion |
CHF19.98 Billion ≈ $25.26 Billion |
0.658x | +5.89% |
| 2017-12-31 | CHF29.01 Billion ≈ $36.67 Billion |
CHF18.02 Billion ≈ $22.79 Billion |
0.621x | +9.36% |
| 2016-12-31 | CHF26.40 Billion ≈ $33.38 Billion |
CHF15.00 Billion ≈ $18.97 Billion |
0.568x | -13.20% |
| 2015-12-31 | CHF23.30 Billion ≈ $29.46 Billion |
CHF15.25 Billion ≈ $19.28 Billion |
0.655x | -11.42% |
| 2014-12-31 | CHF21.56 Billion ≈ $27.26 Billion |
CHF15.93 Billion ≈ $20.14 Billion |
0.739x | -0.48% |
| 2013-12-31 | CHF21.24 Billion ≈ $26.85 Billion |
CHF15.77 Billion ≈ $19.94 Billion |
0.743x | -17.22% |
| 2012-12-31 | CHF16.73 Billion ≈ $21.15 Billion |
CHF15.01 Billion ≈ $18.97 Billion |
0.897x | +0.28% |
| 2011-12-31 | CHF14.48 Billion ≈ $18.31 Billion |
CHF12.95 Billion ≈ $16.38 Billion |
0.894x | -27.27% |
| 2010-12-31 | CHF11.66 Billion ≈ $14.74 Billion |
CHF14.34 Billion ≈ $18.13 Billion |
1.230x | -31.40% |
| 2009-12-31 | CHF9.41 Billion ≈ $11.90 Billion |
CHF16.88 Billion ≈ $21.34 Billion |
1.793x | +692.39% |
| 2008-12-31 | CHF53.82 Billion ≈ $68.05 Billion |
CHF12.18 Billion ≈ $15.40 Billion |
0.226x | +2.83% |
| 2007-12-31 | CHF53.31 Billion ≈ $67.39 Billion |
CHF11.73 Billion ≈ $14.83 Billion |
0.220x | -0.29% |
| 2006-12-31 | CHF46.81 Billion ≈ $59.19 Billion |
CHF10.33 Billion ≈ $13.06 Billion |
0.221x | -7.67% |
| 2005-12-31 | CHF41.74 Billion ≈ $52.77 Billion |
CHF9.97 Billion ≈ $12.61 Billion |
0.239x | +8.46% |
| 2004-12-31 | CHF33.29 Billion ≈ $42.09 Billion |
CHF7.33 Billion ≈ $9.27 Billion |
0.220x | -11.41% |
| 2003-12-31 | CHF29.16 Billion ≈ $36.87 Billion |
CHF7.25 Billion ≈ $9.17 Billion |
0.249x | +552.72% |
| 2002-12-31 | CHF25.77 Billion ≈ $32.58 Billion |
CHF982.00 Million ≈ $1.24 Billion |
0.038x | -74.64% |
| 2001-12-31 | CHF33.87 Billion ≈ $42.82 Billion |
CHF5.09 Billion ≈ $6.43 Billion |
0.150x | +22.90% |
| 2000-12-31 | CHF32.04 Billion ≈ $40.50 Billion |
CHF3.92 Billion ≈ $4.95 Billion |
0.122x | +112.35% |
| 1999-12-31 | CHF30.00 Billion ≈ $37.93 Billion |
CHF1.73 Billion ≈ $2.18 Billion |
0.058x | -63.69% |
| 1998-12-31 | CHF22.82 Billion ≈ $28.84 Billion |
CHF3.62 Billion ≈ $4.57 Billion |
0.159x | -- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more